Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $31.48 Analyst target: $62.54 Upside: 98.67%
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.